Effects of nanoliposomal irinotecan (nal-IRI;MM-398) +/- 5-Fluorouracil und leucavorin (5-FU/LV) on quality of life (QoL) in NAPOLI-1: a phase 3 study in patients (pts) with metastatic pancreatic adenocarcinoma (mPAC) previously treated with gemcitabine-based therapy.
dc.contributor.author | Siveke, J | |
dc.contributor.author | Cubillo, A | |
dc.contributor.author | Blanc, J | |
dc.contributor.author | Melisi, D | |
dc.contributor.author | Von Hoff, D | |
dc.contributor.author | Wang-Gillam, A | |
dc.contributor.author | Chen, L | |
dc.contributor.author | Becker, C | |
dc.contributor.author | Mamlouk, K | |
dc.contributor.author | Belanger, B | |
dc.contributor.author | Yang, Y | |
dc.contributor.author | de Long, F | |
dc.contributor.author | Hubner, Richard A | |
dc.date.accessioned | 2017-08-16T08:41:44Z | |
dc.date.available | 2017-08-16T08:41:44Z | |
dc.date.issued | 2017 | |
dc.identifier.citation | Effects of nanoliposomal irinotecan (nal-IRI;MM-398) +/- 5-Fluorouracil und leucavorin (5-FU/LV) on quality of life (QoL) in NAPOLI-1: a phase 3 study in patients (pts) with metastatic pancreatic adenocarcinoma (mPAC) previously treated with gemcitabine-based therapy. 2017, 40:259-259 Oncol Res Treat | en |
dc.identifier.uri | http://hdl.handle.net/10541/620505 | |
dc.language.iso | en | en |
dc.title | Effects of nanoliposomal irinotecan (nal-IRI;MM-398) +/- 5-Fluorouracil und leucavorin (5-FU/LV) on quality of life (QoL) in NAPOLI-1: a phase 3 study in patients (pts) with metastatic pancreatic adenocarcinoma (mPAC) previously treated with gemcitabine-based therapy. | en |
dc.type | Meetings and Proceedings | en |
dc.contributor.department | University Hospital Essen, West German Cancer Center, Essen, Germany | en |
dc.identifier.journal | Oncology Research and Treatment | en |